Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Pharmacology & Pharmacy2012Vol. 03(04), pp. 481–484
Citations Over Time
Abstract
Antiplatelet therapy, which reduces platelet activation and aggregation, is the corner stone of treatment for patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is an established oral antiplatelet medication of thienopyridine class, which inhibits blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Many studies have revealed that high loading dose clopidogrel in patients undergoing PCI. This review article investigates the rationale and role of high loading dose clopidogrel in patients undergoing PCI.
Related Papers
- → Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention(2012)2 cited
- Abstract 10390: Prasugrel Treatment is More Effective in Reducing Platelet Reactivity in PCI Patients with Low Clopidogrel Response Compared to Dose Increase of Clopidogrel(2011)
- → 1035(2012)
- Progress of the Application of High Loading-and Maintenance-dose Clopidogrel in Acute Coronary Syndrome(2012)
- The Application of High-loading-dose of Clopidogrel in Acute Coronary Syndrome(2008)